Launch of ESMO Virtual Plenaries Brings Rapid Access to Ground-breaking Cancer Research
17.2.2021 15:00:00 EET | Business Wire | Press release
ESMO, the leading organisation for medical oncology, has launched an important new service for rapidly disseminating research to accelerate the transition of results into practice for the benefit of cancer patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217005495/en/
(Graphic: ESMO)
“In a world that runs fast, timeliness in bringing research advances to patients is critical. The lessons that we have learnt from the COVID-19 pandemic have taught us that we need to be creative in sharing research results, and we certainly don’t have to wait for the two or three times in the year when major oncology congresses take place,” says Solange Peters, ESMO President.
ESMO Virtual Plenaries will combine concise presentations of new data, insightful discussion and audience Q&A in live, easy-to-access, 60-minute online sessions at convenient times across international time zones. They will remain available on OncologyPRO, ESMO’s online resource portal, for subsequent viewing.
Every month, latest, original scientific data will be presented from randomised phase III oncology trials or phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need.
“By timely presentation of clinical and scientific data, ESMO Virtual Plenaries will be complementary to and enhance the value of conventional scientific congresses, whilst adhering to the principles of peer review, analysis and audience interaction,” says George Pentheroudakis, ESMO Chief Medical Officer.
A maximum of two abstracts will be accepted for presentation each month (except September and November when ESMO hosts major congresses). Abstracts will be original data from international investigators, selected by appropriate independent ESMO specialists. After presentation and discussion in ESMO Virtual Plenaries, abstracts will be published in Annals of Oncology and will be eligible for encore presentation at the next ESMO Congress.
The first ESMO Virtual Plenary is on Friday, 19 February, 1300 CET
Efficacy of everolimus in patients with HR+/HER2- high risk early-stage breast cancer
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology. ESMO Members or anyone with an already existing free ESMO Account will be able to log in and watch using their existing ESMO Account.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005495/en/
Contact information
European Society for Medical Oncology
Press Office
+41 91 973 19 01
media@esmo.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
Xsolla Launches Game Biz Institute, an Editorial Platform Where Industry Practitioners Explain the Business of Games27.8.2026 18:32:00 EEST | Press release
Xsolla, a global commerce company, today announced the launch of Game Biz Institute (GBI), an editorial platform where named industry practitioners and researchers examine the commercial layer of games: direct-to-player distribution, payments, monetization, user acquisition, and retention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827362663/en/ Graphic: Xsolla Game design has a curriculum. The business of games does not. Engines, pipelines, production, and narrative are taught at hundreds of universities, while the commercial machinery that determines whether good work becomes a durable company is still learned through expensive trial and error, usually after the decisions that mattered have already been made. GBI was built to close that gap by publishing what practitioners have actually learned running these businesses. "Game developers have never had more data and less clarity," said Chris Hewish, President of Xsol
Star Wars Zero Company™ Now Available On PC, PlayStation 5 and XBOX Series Consoles27.8.2026 18:00:00 EEST | Press release
Electronic Arts Inc. and Bit Reactor, in collaboration with Lucasfilm Games, announced today that Star Wars Zero Company™, a single-player turn-based tactics game set in the twilight of the Clone Wars™, is now available for PC via the EA app, Steam, and Epic Games Store, and PlayStation®5 and XBOX Series consoles. In Star Wars Zero Company, former Republic officer Hawks and Zero Company, an elite squad of unconventional professionals for hire, are recruited for an operation by Republic Intelligence. From ex-nobles to ex-cons, they now share one mission: Stop the Infinite Coil, a Separatist-aligned cult, and their leader Kundri Fathom before the deadly Shadow Plague consumes the galaxy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012810/en/ https://www.youtube.com/watch?si=7SYogg8ILAD3tUG3&v=AxAgeglgSeA&feature=youtu.be “After all these years of hard work from our amazing team, Star Wars Zero Company is a go for laun
Rehlko Joins Wisconsin Data Center Coalition as Newest Energy Resilience Member, Reinforcing Its Role at the Center of AI and Digital Infrastructure Growth27.8.2026 16:15:00 EEST | Press release
Rehlko, a global industrial energy resilience platform providing custom-engineered, integrated power solutions for mission-critical infrastructure worldwide, today announced it has joined the Wisconsin Data Center Coalition (WIDCC) as the organization's newest energy resilience member. The membership reflects Rehlko's commitment to advancing Wisconsin's role as a leader in responsible AI infrastructure development, built on reliable and scalable power. Rapid growth in hyperscale and enterprise data center investment is reshaping markets across the world, and Rehlko is building the power infrastructure that makes it possible. Sitting at the intersection of the structural forces driving AI infrastructure expansion, grid reliability, and accelerating electrification, Rehlko brings more than a century of engineering depth and lifecycle capability to the table. WIDCC brings together stakeholders from across Wisconsin's technology, utility, economic development, workforce development, govern
GenNx360 Capital Partners Closes Fourth Flagship Fund at $865 Million27.8.2026 15:30:00 EEST | Press release
GenNx360 Capital Partners (“GenNx360” or “the Firm”), a New York City-based private equity firm investing in U.S. lower middle market industrial services and business services companies, today announced the successful closing of GenNx360 Capital Partners IV, L.P. (“Fund IV” or “the Fund”), with $865 million in commitments, exceeding its target. Fund IV is the largest fund raised in GenNx360’s history. Fund IV was supported by a diverse group of existing and new investors including leading pensions, asset managers, insurance companies, foundations, and family offices, reflecting conviction in the firm’s disciplined investment approach, operational value creation model, and tenured, diverse team. Fund IV will continue GenNx360’s differentiated strategy of partnering with lower middle market founders and management teams to scale essential services businesses. Fund IV has made five investments to date across infrastructure services, testing and inspection services, aerospace and defense,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom